Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents

被引:66
作者
Coplan, PM
Gupta, SB
Dubey, SA
Pitisuttithum, P
Nikas, A
Mbewe, B
Vardas, E
Schechter, M
Kallas, EG
Freed, DC
Fu, TM
Mast, CT
Puthavathana, P
Kublin, J
Collins, KB
Chisi, J
Pendame, R
Thaler, SJ
Gray, G
Mcintyre, J
Straus, WL
Condra, JH
Mehrotra, DV
Guess, HA
Emini, EA
Shiver, JW
机构
[1] Merck Res Labs, West Point, PA USA
[2] Mahidol Univ, Bangkok 10700, Thailand
[3] Malawi Coll Med, Blantyre, Malawi
[4] Minist Populat & Hlth, Lilongwe, Malawi
[5] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil
[6] Univ Fed Sao Paulo, Sao Paulo, Brazil
[7] Univ Witwatersrand, Johannesburg, South Africa
关键词
D O I
10.1086/428450
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The genetic diversity of human immunodeficiency virus type 1 (HIV-1) raises the question of whether vaccines that include a component to elicit antiviral T cell immunity based on a single viral genetic clade could provide cellular immune protection against divergent HIV-1 clades. Therefore, we quantified the cross-clade reactivity, among unvaccinated individuals, of anti-HIV-1 T cell responses to the infecting HIV-1 clade relative to other major circulating clades. Methods. Cellular immune responses to HIV-1 clades A, B, and C were compared by standardized interferon-gamma enzyme-linked immunospot assays among 250 unvaccinated individuals, infected with diverse HIV-1 clades, from Brazil, Malawi, South Africa, Thailand, and the United States. Cross-clade reactivity was evaluated by use of the ratio of responses to heterologous versus homologous ( infecting) clades of HIV-1. Results. Cellular immune responses were predominantly focused on viral Gag and Nef proteins. Cross-clade reactivity of cellular immune responses to HIV-1 clade A, B, and C proteins was substantial for Nef proteins ( ratio, 0.97 [95% confidence interval, 0.89-1.05]) and lower for Gag proteins ( ratio, 0.67 [ 95% confidence interval, 0.62-0.73]). The difference in cross-clade reactivity to Nef and Gag proteins was significant (P < .0001). Conclusions. Cross-clade reactivity of cellular immune responses can be substantial but varies by viral protein.
引用
收藏
页码:1427 / 1434
页数:8
相关论文
共 39 条
[1]   The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals [J].
Addo, MM ;
Altfeld, M ;
Rosenberg, ES ;
Eldridge, RL ;
Philips, MN ;
Habeeb, K ;
Khatri, A ;
Brander, C ;
Robbins, GK ;
Mazzara, GP ;
Goulder, PJR ;
Walker, BD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) :1781-1786
[2]  
Auswinporn Somsri, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P346
[3]   HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe [J].
Batra, M ;
Tien, PC ;
Shafer, RW ;
Contag, CH ;
Katzenstein, DA .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (10) :973-979
[4]   Controlling the false discovery rate in behavior genetics research [J].
Benjamini, Y ;
Drai, D ;
Elmer, G ;
Kafkafi, N ;
Golani, I .
BEHAVIOURAL BRAIN RESEARCH, 2001, 125 (1-2) :279-284
[5]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[6]   Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians [J].
Betts, MR ;
Krowka, J ;
Santamaria, C ;
Balsamo, K ;
Gao, F ;
Mulundu, G ;
Luo, CW ;
NGandu, N ;
Sheppard, H ;
Hahn, BH ;
Allen, S ;
Frelinger, JA .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8908-8911
[7]   Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: Relevance to HIV-1 vaccine trials in Uganda [J].
Cao, HY ;
Mani, I ;
Vincent, R ;
Mugerwa, R ;
Mugyenyi, P ;
Kanki, P ;
Ellner, J ;
Walker, BD .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (05) :1350-1356
[8]   Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development [J].
Cao, HY ;
Kanki, P ;
Sankale, JL ;
DiengSarr, A ;
Mazzara, GP ;
Kalams, SA ;
Korber, B ;
Mboup, S ;
Walker, BD .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8615-8623
[9]   A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays [J].
Currier, JR ;
Kuta, EG ;
Turk, E ;
Earhart, LB ;
Loomis-Price, L ;
Janetzki, S ;
Ferrari, G ;
Birx, DL ;
Cox, JH .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 260 (1-2) :157-172
[10]   Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients [J].
Durali, D ;
Morvan, J ;
Letourneur, F ;
Schmitt, D ;
Guegan, N ;
Dalod, M ;
Saragosti, S ;
Sicard, D ;
Levy, JP ;
Gomard, E .
JOURNAL OF VIROLOGY, 1998, 72 (05) :3547-3553